HomeAI · summaries
Storia in 2 fonti
Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial
Three years after gaining three liver disease assets in its $952 million buyout of Alb | Three years after gaining three liver disease assets in its $952 million buyout of Albireo, Ipsen is struggling to develop the trio. The company has reported the failure of liver disease drug Bylvay in a phase 3 study in biliary atresia.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial
Three years after gaining three liver disease assets in its $952 million buyout of Alb | Three years after gaining three liver disease assets in its $952 million buyout of…
- ·
endpoints.news
Ipsen’s Bylvay fails key trial in children with rare liver disease
Ipsen disclosed that Bylvay failed a Phase 3 study for biliary atresia, a serious liver disease that leads the bile ducts to become blocked in babies.